In our cross-sectional analysis of patients undergoing PCI for either non-ACS or ACS indications, we found substantial use of prasugrel and ticagrelor in both groups. Despite limited current evidence to support prasugrel or ticagrelor in SIHD, over one-third of non-ACS patients received one of the newer P2Y 12 inhibitors in 2016. Reasons for this may include increasing clinician comfort with novel medications over time, targeting of newer agents to patients with perceived elevated risk of future cardiac events, and extension of trial results seen in ACS patients to SIHD patients.
Our recent study found that PCI patients prescribed prasugrel or ticagrelor had lower rates of adherence and incurred higher out-of-pocket costs than patients prescribed clopidogrel. 3 In the absence of clinical trials demonstrating benefit for prasugrel and ticagrelor use in SIHD patients treated with PCI, clinicians should be judicious in using these agents for off-label indications. The role of prasugrel and ticagrelor in elective PCI remains under active investigation. 4 Studies such as the ongoing ALPHEUS trial (Assessment of Loading with a new P2Y 12 inhibitor or clopidogrel to Halt ischemic Events in patients Undergoing elective coronary Stenting) may better elucidate the appropriate role of these agents for higher-risk patients.
2,5 Also of future interest will be the evaluation of potential benefits of pharmacogenetictailored antiplatelet therapy in this population.
This study has limitations inherent to retrospective studies using administrative claims. Primary clinical data were not available; however, we used well-validated administrative codes for ACS and PCI to optimally identify patients. We did not have detailed anatomic data to evaluate for higher-risk features for ischemic events nor details about phenotypic/genotypic assessment of platelet reactivity. We also only included patients who filled a prescription within 30 days of PCI, thus prescriptions written for nonadherent patients could not be observed. Last, the sample came from commercially insured, nonelderly patients; thus our results may not apply to the elderly and to patients with public health insurance.
In conclusion, off-label use of prasugrel and ticagrelor in PCI patients with SIHD is common, despite the lack of current clear evidence to support its routine use in SIHD. The dark blue, light blue, and medium blue bars represent the percent of PCI patients filling a prescription within 30 days of discharge for clopidogrel, prasugrel, and ticagrelor, respectively. A, Includes patients with a nonacute coronary syndrome (ACS) indication for PCI (n=6959), and (B) includes patients with ACS as indication for PCI (n=35 724).
